| Q24535020 | A role for the melanocortin 4 receptor in sexual function |
| Q48327568 | Ac-nle-c[asp-his-dphe-arg-trp-lys]-nh2 induces penile erection via brain and spinal melanocortin receptors |
| Q34157024 | Activation of melanocortin MC(4) receptors increases erectile activity in rats ex copula |
| Q35545746 | Animal models in urological disease and sexual dysfunction |
| Q30354242 | Antiobesity pharmacotherapy: new drugs and emerging targets |
| Q36170873 | Approaches to the rational design of selective melanocortin receptor antagonists |
| Q73293522 | Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII |
| Q39256591 | Biased signaling at neural melanocortin receptors in regulation of energy homeostasis |
| Q40580707 | Biological and conformational study of beta-substituted prolines in MT-II template: steric effects leading to human MC5 receptor selectivity |
| Q34629614 | Central nervous system agents and erectile dysfunction. |
| Q36314067 | Central nervous system agents in the treatment of erectile dysfunction |
| Q36993652 | Centrally acting mechanisms for the treatment of male sexual dysfunction |
| Q46440004 | Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response |
| Q46987673 | Co-treatment with melanotan-II, a potent melanocortin, does not protect against cisplatin ototoxicity |
| Q33926210 | Conformational study on cyclic melanocortin ligands and new insight into their binding mode at the MC4 receptor |
| Q37365405 | Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles |
| Q34703179 | Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities |
| Q44764463 | Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction |
| Q35750424 | Effects of macrocycle size and rigidity on melanocortin receptor-1 and -5 selectivity in cyclic lactam alpha-melanocyte-stimulating hormone analogs |
| Q34586801 | Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. |
| Q44785618 | Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra |
| Q35166372 | Female sexual dysfunction: potential for pharmacotherapy |
| Q34029414 | Future prospects in the treatment of erectile dysfunction: focus on avanafil. |
| Q57295893 | Genetic variation in the locus is associated with erectile dysfunction |
| Q101564372 | Genetics and erectile dysfunction: leveraging early foundations for new discoveries |
| Q87766471 | Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet |
| Q34677765 | Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects |
| Q37058008 | Looking to the future for erectile dysfunction therapies |
| Q52686348 | MC4R Agonists: Structural Overview on Antiobesity Therapeutics. |
| Q24647691 | Melanocortin receptors, melanotropic peptides and penile erection |
| Q36181835 | Melanocortinergic control of penile erection |
| Q36170863 | Melanotropins as drugs for the treatment of obesity and other feeding disorders: potential and problems |
| Q33585575 | Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies |
| Q90581717 | Novel Emerging Therapies for Erectile Dysfunction |
| Q24315086 | Novel binding motif of ACTH analogues at the melanocortin receptors |
| Q34583191 | Organic chemistry and biology: chemical biology through the eyes of collaboration |
| Q35597667 | Recent developments in our understanding of melanocortin system in the regulation of food intake |
| Q30359853 | Reduced melanocortin production causes sexual dysfunction in male mice with POMC neuronal insulin and leptin insensitivity. |
| Q34377037 | Role of melanocortins in control of obesity |
| Q47749050 | Sexual function following radical prostatectomy: a prospective longitudinal study of cultural differences between Japanese and American men. |
| Q50069050 | Sim1 Neurons Are Sufficient for MC4R-Mediated Sexual Function in Male Mice |
| Q35924319 | Specific aspects of erectile dysfunction in endocrinology |
| Q24653947 | Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 receptor |
| Q37417029 | Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 receptor |
| Q28273671 | The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases |
| Q39254824 | The melanocortin 1 receptor (MC1R) inhibits the inflammatory response in Raw 264.7 cells and atopic dermatitis (AD) mouse model |
| Q37313789 | The melanocortin circuit in obese and lean strains of chicks |
| Q36003378 | The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. |
| Q34635467 | The role of melanocortins in body weight regulation: opportunities for the treatment of obesity |
| Q74604281 | The role of melanocortins in body weight regulation: opportunities for the treatment of obesity |
| Q83869240 | [New strategies of photoprotection] |